Generic Conversions And Margin ExpansionClear visibility into generic conversions enables shifting volume to higher-margin products, driving gross profit improvement and sustaining EBITDA expansion.
Limited Distribution Drug WinsOnco360's strong track record of winning limited distribution oncology drugs positions the company to secure exclusive contracts on new launches, supporting specialty pharmacy revenue expansion and top-line growth in 2026.
Provider Services Integration And Nationwide Palliative RolloutIntegration of Provider Services with a nationwide palliative program rollout in 2026 strengthens home-and-community care synergies, supporting above-peer revenue growth and higher-margin service mix.